Febuxostat for Treatment of Chronic Gout

Charnelda L. Gray, Pharm.D., BCPS; Nafesa E. Walters-Smith, Pharm.D., BCPS

Disclosures

Am J Health Syst Pharm. 2011;68(5):389-398. 

In This Article

Dosage and Administration

Febuxostat was approved for the chronic management of hyperuricemia in patients with gout, with recommended dosages of 40 and 80 mg once daily.[30] The recommended initial dosage of febuxostat is 40 mg orally once daily with or without food. The target serum uric acid concentration is <6 mg/dL. Prophylaxis is recommended due to the risk of an acute gouty flare. Prophylaxis may by warranted for an extended period of time as patients receiving febuxostat monotherapy developed flares frequently.[26] The manufacturer recommends flare prophylaxis with NSAIDs or colchicine.[30] If the target serum uric acid concentration is not reached after two weeks, the dosage of febuxostat may be increased to 80 mg orally once daily. Patients with mild-to-moderate hepatic or renal impairment do not require additional dosage adjustments. However, caution should be encouraged in patients with severe renal insufficiency (CLcr of <30 mL/min) or severe hepatic impairment (Child-Pugh class C). Although the 120-mg dose was evaluated in clinical trials, that dosage is not in the approved labeling. Dosages of febuxostat should be adjusted to achieve serum uric acid concentrations of <6 mg/dL.[27]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....